A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders.

Abstract

Most biomarker candidates arising from proteomic studies of psychiatric disorders have not progressed for use in clinical studies due to insufficient validation steps. Here we describe a selective reaction monitoring mass spectrometry (SRM-MS) approach that could be used as a follow-up validation tool of proteins identified in blood serum or plasma. This protocol specifically covers the stages of peptide selection and optimization. The increasing application of SRM-MS should enable fast, sensitive, and robust methods with the potential for use in clinical studies involving sampling of serum or plasma. Understanding the molecular mechanisms and identifying potential biomarkers for risk assessment, diagnosis, prognosis, and prediction of drug response goes toward the implementation of translational medicine strategies for improved treatment of patients with psychiatric disorders and other debilitating diseases.

• Authors: Guilherme Reis-de-Oliveira, Sheila Garcia, Paul C Guest, Juliana S Cassoli, Daniel Martins-de-Souza
• Journal: Advances in experimental medicine and biology (Adv Exp Med Biol) Vol. 974 Pg. 213-218 ( 2017) ISSN: 0065-2598 [Print] United States
• PMID: 28353238 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Nerve Tissue Proteins
• Peptide Fragments

Topics

• Biomarkers (blood)
• Brain Chemistry
• Humans
• Mass Spectrometry (instrumentation, methods)
• Mental Disorders (blood)
• Nerve Tissue Proteins (blood)
• Peptide Fragments (blood)
• Plasma
• Serum